Journal of the neurological sciences · 2026
Reduction of interleukin-6 levels in patients with Friedreich's Ataxia treated with omaveloxolone.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Di Stefano Vincenzo, Lima Salvatore Maria, Campo Sofia, Mancuso Perla, Quartetti Umberto, Rini Nicasio, Brighina Filippo, Labate Angelo
Аннотация
BACKGROUND: Friedreich's Ataxia (FRDA) is the most common inherited spinocerebellar ataxia and is caused by a homozygous GAA trinucleotide repeat expansion in the frataxin (FXN) gene, leading to reduced intramitochondrial frataxin expression with a consequent progressive neurodegeneration and multisystem involvement. Neuroinflammatory pathways may contribute to FRDA pathophysiology and IL-6 represents a biologically relevant inflammatory mediator. Recently, omaveloxolone (Omav), an activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, demonstrated clinically meaningful neurological benefits with a favorable safety profile.
OBJECTIVES: In this study, we report a 1-year follow-up of our real-life population treated with Omav, with a specific focus on clinical outcomes, safety, and inflammatory biomarkers.
METHODS: Twenty patients with FRDA were evaluated for 48 weeks using clinical scales (mFARS, SARA, FSS, and FA-ADL) and laboratory testing. Inclusion criteria were genetically confirmed FRDA, age ≥ 16 years and mFARS <80. All patients received Omav 150 mg/day.
RESULTS: Treatment showed a favorable safety profile, clinical stabilization and no serious adverse events with only one treatment discontinuation. IL-6 levels showed a progressive and significant reduction during follow-up. Transient hepatic enzyme elevations did not lead to treatment discontinuation.
CONCLUSIONS: Omav confirmed a favorable safety and tolerability profile in adult patients with FRDA in a real-world setting after 48 weeks of treatment. The sustained reduction in IL-6 levels further supports a potential direct immunomodulatory effect of the drug, consistent with its proposed disease-modifying activity. However, further long-term studies are warranted to better define the efficacy of Omav in FRDA.
OBJECTIVES: In this study, we report a 1-year follow-up of our real-life population treated with Omav, with a specific focus on clinical outcomes, safety, and inflammatory biomarkers.
METHODS: Twenty patients with FRDA were evaluated for 48 weeks using clinical scales (mFARS, SARA, FSS, and FA-ADL) and laboratory testing. Inclusion criteria were genetically confirmed FRDA, age ≥ 16 years and mFARS <80. All patients received Omav 150 mg/day.
RESULTS: Treatment showed a favorable safety profile, clinical stabilization and no serious adverse events with only one treatment discontinuation. IL-6 levels showed a progressive and significant reduction during follow-up. Transient hepatic enzyme elevations did not lead to treatment discontinuation.
CONCLUSIONS: Omav confirmed a favorable safety and tolerability profile in adult patients with FRDA in a real-world setting after 48 weeks of treatment. The sustained reduction in IL-6 levels further supports a potential direct immunomodulatory effect of the drug, consistent with its proposed disease-modifying activity. However, further long-term studies are warranted to better define the efficacy of Omav in FRDA.